A systematic review of brachytherapy: Is it an effective and safe treatment for localised prostate cancer?

Australian Family Physician

Volumn 33, Issue 7, 2004, Pages 525-530

  Doust, Jenny ^a   Miller, Emma ^b   Duchesne, Gillian ^c   Kitchener, Michael ^d   Weller, David ^e  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b DEPARTMENT OF HUMAN SERVICES   (Australia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d QUEEN ELIZABETH HOSPITAL   (Australia)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRACHYTHERAPY; CANCER STAGING; GENERAL PRACTICE; HUMAN; IMPOTENCE; MALE; METHODOLOGY; PATHOLOGY; PROSTATE TUMOR; REVIEW; TREATMENT OUTCOME; URETHRA STRICTURE; URINE INCONTINENCE; URINE RETENTION;

BRACHYTHERAPY; FAMILY PRACTICE; HUMANS; IMPOTENCE; MALE; NEOPLASM STAGING; PROSTATIC NEOPLASMS; TREATMENT OUTCOME; URETHRAL STRICTURE; URINARY INCONTINENCE; URINARY RETENTION;

EID: 4444351958     PISSN: 03008495     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. King CR, DiPetrillo TA, Wazer DE. Optimal radiotherapy for prostate cancer: predictions for conventional external beam, IMRT, and brachytherapy from radiobiologic models. Int J Radiat Oncol Biol Phys 2000;46:165-172.
2. Crook J, Lukka H, Klotz L, Bestic N, Johnston M. Systematic overview of the evidence for brachytherapy in clinically localised prostate cancer. CMAJ 2001;164:975-981.
3. Wills F, Hailey D. Brachytherapy for prostate cancer. In: The Alberta Heritage Foundation for Medical Research. Alberta: 1999.
4. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localised prostate cancer. JAMA 1998;280:969-974.
5. King C, Sanzone J, Anderson K, Schel R. Definitive therapy for stage T1/T2 prostate carcinoma: PSA based comparison between surgery, external beam, and implant radiotherapy. Journal of Brachytherapy International 1998;14:169-177.
6. Stokes SH. Comparison of biochemical disease free survival of patients with localised carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound guided radioactive seed implantation, or definitive external beam irradiation. Int J Radiat Oncol Biol Phys 2000;47:129-136.
7. Brachman DG, Thomas T, Hilbe J, Beyer DC. Failure free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumours in 2222 patients: results from a single practice. Int J Radiat Oncol Biol Phys 2000;48:111-117.
8. Beyer DC, Brachman DG. Failure free survival following brachytherapy alone for prostate cancer: comparison with external beam radiotherapy. Radiother Oncol 2000;57:263-267.
9. Sharkey J, Cantor A, Solc Z, et al. Brachytherapy versus radical prostatectomy in patients with clinically localised prostate cancer. Curr Urol Rep 2002;3:250-257.
10. Zelefsky MJ, Wallner KE, Ling CC, et al. Comparison of the 5 year outcome and morbidity of three dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early stage prostatic cancer. J Clin Oncol 1999;17:517-522.
11. Grado GL, Larson TR, Balch CS, et al. Actuarial disease free survival after prostate cancer brachytherapy using interactive techniques with biplane ultrasound and fluoroscopic guidance. Int J Radiat Oncol Biol Phys 1998;42:289-298.
12. Kwok Y, DiBiase SJ, Amin PP, Naslund M, Sklar G, Jacobs SC. Risk group stratification in patients undergoing permanent 125I prostate brachytherapy as monotherapy. Int J Radiat Oncol Biol Phys 2002;53:588-594.
13. Storey MR, Landgren RC, Cottone JL, et al. Transperineal 125iodine implantation for treatment of clinically localised prostate cancer: 5 year tumour control and morbidity. Int J Radiat Oncol Biol Phys 1999;43:565-570.
14. Blasko JC, Wallner K, Grimm PD, Ragde H. Prostate specific antigen based disease control following ultrasound guided 125iodine implantation for stage T1/T2 prostatic carcinoma. J Urol 1995;154:1096-1099.
15. Blasko JC, Grimm PD, Sylvester JE, Badiozamani KR, Hoak D, Cavanagh W. Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 2000;46:839-850.
16. Grimm PD, Blasko JC, Sylvester JE, Meier RM, Cavanagh W. 10 year biochemical (prostate specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys 2001;51:31-40.
17. Prestidge BR, Hoak DC, Grimm PD, Ragde H, Cavanagh W, Blasko JC. Post-treatment biopsy results following interstitial brachytherapy in early stage prostate cancer. Int J Radiat Oncol Biol Phys 1997;37:31-39.
18. Ragde H, Blasko JC, Grimm PD, et al. Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localised prostate carcinoma. Cancer 1997;80:442-453.
19. Ragde H, Blasko JC, Grimm PD, et al. Brachytherapy for clinically localised prostate cancer: results at 7 and 8 year follow up. Semin Surg Oncol 1997;13:438-443.
20. Ragde H, Elgamal AA, Snow PB, et al. Ten year disease free survival after transperineal sonography guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localised, low to high Gleason grade prostate carcinoma. Cancer 1998;83:989-1001.
21. Ragde H, Korb L. Brachytherapy for clinically localised prostate cancer. Semin Surg Oncol 2000a;18:45-51.
22. Ragde H, Grado GL, Nadir B, Elgamal AA. Modern prostate brachytherapy. CA Cancer J Clin 2000b;50:380-93.
23. Ragde H, Korb LJ, Elgamal AA, Grado GL, Nadir BS. Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow up. Cancer 2000;89:135-141.
24. Ragde H, Grado GL, Nadir BS. Brachytherapy for clinically localised prostate cancer: thirteen year disease free survival of 769 consecutive prostate cancer patients treated with permanent implants alone. Arch Esp Urol 2001;54:739-747.
25. Sharkey J, Chovnick SD, Behar RJ, et al. Minimally invasive treatment for localised adenocarcinoma of the prostate: review of 1048 patients treated with ultrasound guided palladium- 103 brachytherapy. J Endourol 2000;14:343-350.
26. Sharkey J, Chovnick SD, Behar RJ, et al. Evolution of techniques for ultrasound guided palladium 103 brachytherapy in 950 patients with prostate cancer. Tech Urol 2000;6:128-134.
27. Stock RG, Stone NN, DeWyngaert JK, Lavagnini P, Unger PD. Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma. Cancer 1996;77:2386-2392.
28. Stone NN, Stock RG, Unger P, Kao J. Biopsy results after real time ultrasound guided transperineal implants for stage T1-T2 prostate cancer. J Endourol 2000;14:375-380.
29. Potters L, Cha C, Oshinsky G, Venkatraman E, Zelefsky M, Leibel S. Risk profiles to predict PSA relapse free survival for patients undergoing permanent prostate brachytherapy. Cancer J Sci Am 1999;5:301-306.
30. Potters L. Permanent prostate brachytherapy: lessons learned, lessons to learn. Oncology 2000;14:981-991, 991-992, 997-999.
31. Wallner K, Roy J, Zelefsky M, Fuks Z, Harrison L. Short term freedom from disease progression after I-125 prostate implantation. Int J Radiat Oncol Biol Phys 1994;30:405-409.
32. Zelefsky MJ, Hollister T, Raben A, Matthews S, Wallner KE. Five year biochemical outcome and toxicity with transperineal CT planned permanent I-125 prostate implantation for patients with localised prostate cancer. Int J Radiat Oncol Biol Phys 2000;47:1261-1266.
33. Walther PJ. Interstitial brachytherapy for prostate cancer: just an expensive variant of 'watchful waiting'? Curr Opin Urol 1999;9:201-204.
34. Zietman AL, Thakral H, Wilson L, Schellhammer P. Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy. J Urol 2001;166:1702-1706.
35. Wallner K, Merrick G, True L, Cavanagh W, Simpson C, Butler W. I-125 versus Pd-103 for low risk prostate cancer: morbidity outcomes from a prospective randomised multicenter trial. Cancer J 2002;8:67-73.
36. Lee WR, Hall MC, McQuellon RP, Case LD, McCullough DL. A prospective quality of life study in men with clinically localised prostate carcinoma treated with radical prostatectomy, external beam radiotherapy, or interstitial brachytherapy. Int J Radiat Oncol Biol Phys 2001;51:614-623.
37. Davis JW, Kuban DA, Lynch DF, Schellhammer PF. Quality of life after treatment for localised prostate cancer: differences based on treatment modality. J Urol 2001;166:947-952.
38. Wei JT, Dunn RL, Sandler HM, et al. Comprehensive comparison of health related quality of life after contemporary therapies for localised prostate cancer. J Clin Oncol 2002;20:557-566.
39. Benoit RM, Naslund MJ, Cohen JK. Complications after prostate brachytherapy in the Medicare population. Urology 2000;55:91-96.
40. Benoit RM, Naslund MJ, Cohen JK. A comparison of complications between ultrasound guided prostate brachytherapy and open prostate brachytherapy. Int J Radiat Oncol Biol Phys 2000;47:909-913.
41. Bacon CG, Giovannucci E, Testa M, Kawachi I. The impact of cancer treatment on quality of life outcomes for patients with localised prostate cancer. J Urol 2001;166:1804-1810.
42. Krupski T, Petroni GR, Bissonette EA, Theodorescu D. Quality of life comparison of radical prostatectomy and interstitial brachytherapy in the treatment of clinically localised prostate cancer. Urology 2000;55:736-742.
43. Ankem MK, DeCarvalho VS, Harangozo AM, et al. Implications of radioactive seed migration to the lungs after prostate brachytherapy. Urology 2002;59:555-559.
44. Arterbery VE, Frazier A, Dalmia P, Siefer J, Lutz M, Porter A. Quality of life after permanent prostate implant. Semin Surg Oncol 1997;13:461-464.
45. Blatt HJ, Abel LJ, Stipetich RL, et al. Utilisation of a self administered questionnaire to assess rectal function following prostate brachytherapy. Urol Nurs 2001;21:356-359.
46. Brown D, Colonias A, Miller R, et al. Urinary morbidity with a modified peripheral loading technique of transperineal (125)I prostate implantation. Int J Radiat Oncol Biol Phys 2000;47:353-360.
47. Bucci J, Morris WJ, Keyes M, Spadinger I, Sidhu S, Moravan V. Predictive factors of urinary retention following prostate brachytherapy. Int J Radiat Oncol Biol Phys 2002;53:91-98.
48. Crook J, McLean M, Catton C, Yeung I, Tsihlias J, Pintilie M. Factors influencing risk of acute urinary retention after TRUS guided permanent prostate seed implantation. Int J Radiat Oncol Biol Phys 2002;52:453-460.
49. Ellis RJ, Sodee DB, Spirnak JP, et al. Feasibility and acute toxicities of radioimmunoguided prostate brachytherapy. Int J Radiat Oncol Biol Phys 2000;48:683-687.
50. Thomas MD, Cormack R, Tempany CM, et al. Identifying the predictors of acute urinary retention following magnetic resonance guided prostate brachytherapy. Int J Radiat Oncol Biol Phys 2000;47:905-908.
51. Han BH, Demel KC, Wallner K, Ellis W, Young L, Russell K. Patient reported complications after prostate brachytherapy. J Urol 2001;166:953-957.
52. Older RA, Synder B, Krupski TL, Glembocki DJ, Gillenwater JY. Radioactive implant migration in patients treated for localised prostate cancer with interstitial brachytherapy. J Urol 2001;165:1590-1592.
53. Potters L, Torre T, Fearn PA, Leibel SA, Kattan MW. Potency after permanent prostate brachytherapy for localised prostate cancer. Int J Radiat Oncol Biol Phys 2001;50:1235-1242.
54. Talcott JA, Clark JA, Stark PC, Mitchell SP. Long term treatment related complications of brachytherapy for early prostate cancer: a survey of patients previously treated. J Urol 2001;166:494-499.
55. Holmberg L, Bill-Axelson A, Helgesen F et al. A randomised trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002;347:781-789.
56. Moon TD, Brawer MK, Wilt TJ. Prostate Intervention Versus Observation Trial (PIVOT): a randomised trial comparing radical prostatectomy with palliative expectant management for treatment of clinically localised prostate cancer. PIVOT Planning Committee. J Natl Cancer Inst Monogr 1995;19:69-71.
57. Krumholtz JS, Michalski JM, Sundaram CP. Health related quality of life and morbidity in patients receiving brachytherapy for clinically localised prostate cancer. J Endourol 2000;14:371-374.
58. Desai J, Stock RG, Stone NN, Iannuzzi C, DeWyngaert JK. Acute urinary morbidity following I-125 interstitial implantation of the prostate gland. Radiat Oncol Investig 1998;6:135-141.
59. Sanchez-Ortiz RF, Broderick GA, Rovner ES, Wein AJ, Whittington R, Malkowicz SB. Erectile function and quality of life after interstitial radiation therapy for prostate cancer. Int J Impot Res 2000;12(Suppl 3):S18-S24.
60. Koutrouvelis PG. Three dimensional stereotactic posterior ischiorectal space computerised tomography guided brachytherapy of prostate cancer: a preliminary report. J Urol 1998;159:142-145.
61. Blasko JC, Grimm PD, Ragde H. Brachytherapy and Organ Preservation in the Management of Carcinoma of the Prostate. Semin Radiat Oncol 1993;3:240-249.
62. Gelblum DY, Potters L. Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2000;48:119-124